Stephens Inc. AR trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 0.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 118,355 shares of the medical technology company’s stock after selling 1,135 shares during the period. Stephens Inc. AR’s holdings in Medtronic were worth $10,132,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Strategic Financial Services Inc boosted its stake in shares of Medtronic by 1.0% during the 2nd quarter. Strategic Financial Services Inc now owns 57,707 shares of the medical technology company’s stock valued at $4,940,000 after buying an additional 554 shares during the period. D.B. Root & Company LLC boosted its stake in shares of Medtronic by 4.4% during the 2nd quarter. D.B. Root & Company LLC now owns 13,515 shares of the medical technology company’s stock valued at $1,157,000 after buying an additional 564 shares during the period. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Medtronic by 7.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 9,251 shares of the medical technology company’s stock valued at $792,000 after buying an additional 622 shares during the period. Neville Rodie & Shaw Inc. boosted its stake in shares of Medtronic by 3.4% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 19,544 shares of the medical technology company’s stock valued at $1,673,000 after buying an additional 641 shares during the period. Finally, Franklin Parlapiano Turner & Welch LLC boosted its stake in shares of Medtronic by 1.1% during the 2nd quarter. Franklin Parlapiano Turner & Welch LLC now owns 58,125 shares of the medical technology company’s stock valued at $4,976,000 after buying an additional 644 shares during the period. Hedge funds and other institutional investors own 79.80% of the company’s stock.

A number of equities research analysts have issued reports on MDT shares. SunTrust Banks lifted their target price on shares of Medtronic to $96.00 and gave the company a “buy” rating in a research note on Monday, May 21st. TheStreet raised shares of Medtronic from a “c+” rating to a “b-” rating in a research note on Monday, May 21st. Oppenheimer reissued a “buy” rating and set a $96.00 target price on shares of Medtronic in a research note on Thursday, May 24th. Morgan Stanley lifted their target price on shares of Medtronic from $90.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, May 25th. Finally, Piper Jaffray Companies lifted their price objective on shares of Medtronic to $96.00 and gave the company an “overweight” rating in a research note on Friday, May 25th. Eight research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $100.61.

Shares of MDT stock traded down $0.23 on Friday, hitting $96.58. The company’s stock had a trading volume of 23,236 shares, compared to its average volume of 5,399,607. The company has a current ratio of 2.46, a quick ratio of 2.06 and a debt-to-equity ratio of 0.47. Medtronic PLC has a fifty-two week low of $76.41 and a fifty-two week high of $97.38. The firm has a market cap of $129.45 billion, a PE ratio of 20.25, a PEG ratio of 2.53 and a beta of 0.94.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, August 21st. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.06. Medtronic had a net margin of 10.56% and a return on equity of 12.98%. The business had revenue of $7.38 billion during the quarter, compared to analyst estimates of $7.24 billion. During the same quarter in the previous year, the business earned $1.12 EPS. Medtronic’s quarterly revenue was down .1% compared to the same quarter last year. analysts forecast that Medtronic PLC will post 5.12 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 19th. Shareholders of record on Friday, September 28th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date is Thursday, September 27th. Medtronic’s dividend payout ratio is 41.93%.

In other news, Director Richard H. Anderson bought 2,600 shares of the business’s stock in a transaction on Thursday, August 23rd. The stock was purchased at an average price of $95.88 per share, with a total value of $249,288.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Bradley E. Lerman sold 8,910 shares of the business’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $86.82, for a total transaction of $773,566.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 213,130 shares of company stock valued at $20,198,248. Company insiders own 0.31% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Recommended Story: Short Selling Stocks, A Beginner’s Guide

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.